STOCK TITAN

Cocrystal Pharma (COCP) Stock News, Oct-Dec 2022

COCP NASDAQ

Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.

Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.

Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) has presented progress on its CC-42344 influenza treatment at the World Antiviral Congress 2022. The Phase 1 study results indicate a favorable safety profile and potential clinical benefits against various influenza A strains. Plans are underway to report topline results by year-end 2022 and initiate a Phase 2a human challenge trial in 2023. The drug, a PB2 inhibitor, shows promise against seasonal and pandemic strains, notably with a high barrier to resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) announced positive results from the ongoing Phase 1 study of CC-42344, an oral antiviral for influenza A, showing a favorable safety profile in both single-ascending and multiple-ascending dose portions. The trial supports once-daily dosing, with topline results expected by the end of 2022. CC-42344 targets all major influenza A strains, demonstrating excellent antiviral activity. The company plans to submit an application for a Phase 2a human challenge study in early 2023, aiming to initiate the trial in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (COCP) announced complete enrollment in its Phase 1 study for the antiviral candidate CC-42344 targeting influenza A, with topline results expected in late 2022. The company has selected CDI-988 as its lead candidate for SARS-CoV-2, planning to initiate a Phase 1 trial in early 2023. Financial results reveal an increase in R&D expenses to $3.9 million in Q3 2022 from $2.1 million in Q3 2021, and a net loss of $5.7 million. Cash reserves totaled $42.1 million, sufficient to fund operations for three years. Regulatory submissions for further clinical studies are anticipated in early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced participation in two investor conferences. On November 3, CFO James Martin will join a panel at the 2022 BioFlorida Annual Conference focusing on infectious diseases, held at Hyatt Regency Miami. Additionally, he will present a company overview at the Q4 Investor Summit on November 14 at Sheraton New York Time Square Hotel. A webcast of the Q4 Investor Summit will be available on the company’s IR Calendar page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
conferences
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) has been granted European patent EP3866778 for its oral PB2 inhibitor CC-42344, which may enhance treatment options against influenza when used with established antivirals like Tamiflu® and Xofluza®. The company recently completed enrollment in a Phase 1 study for CC-42344 and expects topline results soon. This patent represents a critical step in safeguarding their antiviral innovations in the EU and supports similar efforts globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) has completed enrollment for its Phase 1 healthy volunteer study of CC-42344, a novel antiviral aimed at treating influenza A. This Phase 1 study, initiated in March 2022, assessed safety and pharmacokinetics. Following positive single-ascending-dose results announced in July, the company is moving forward with a Phase 2a human challenge study expected to start in H2 2023, pending regulatory approval. CC-42344 has shown effectiveness against seasonal strains and demonstrated a favorable safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and co-interim CEO Sam Lee, PhD, will present a company overview focusing on antiviral programs and clinical trials at the LD Micro Main Event XV. The presentation is scheduled for October 26, 2022, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time) at the Luxe Sunset Boulevard Hotel, Los Angeles. Interested parties can access the live webcast and archived presentation on the IR Calendar of the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) will present data from its Phase 1 clinical trial of CC-42344, a novel antiviral targeting influenza A, at the upcoming World Antiviral Congress on December 1, 2022. Dr. Sam Lee, co-interim CEO, expressed excitement about sharing this first-in-human trial data, which aims to address both seasonal and pandemic influenza. The company plans to initiate a Phase 2a human challenge trial, leveraging advanced antiviral technology with a promising safety profile. The global influenza therapeutics market is expected to grow, reaching $9.5 billion by 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
conferences clinical trial
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has chosen its antiviral drug candidate CDI-988 for clinical development as an oral treatment for COVID-19. This candidate targets a key region in the SARS-CoV-2 main protease, showcasing superior in vitro potency compared to competitors. With favorable safety and pharmacokinetic profiles, CDI-988 is positioned for a first-in-human trial in Australia anticipated in Q1 2023, following IND-enabling toxicology studies. Cocrystal aims to advance antiviral therapeutics to combat various viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
clinical trial covid-19
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, at 1:00 p.m. Eastern time. The event is scheduled at the Wyndham Grand Hotel in Jupiter, Florida. Mr. Martin will also be available for one-on-one meetings throughout the conference. The presentation will be accessible on the company's website starting October 12.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences

FAQ

What is the current stock price of Cocrystal Pharma (COCP)?

Cocrystal Pharma (COCP) last closed at $0.9769.

What is the market cap of Cocrystal Pharma (COCP)?

The market cap of Cocrystal Pharma (COCP) is approximately $18.8M.